Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALENT: Tegoprazan vs Lansoprazole in Bleeding Peptic Ulcer
NCT06894992Recruiting
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of tegoprazan in peptic ulcer disease (PUD) (2 arms). Primary endpoint: Healing Rate at 2 weeks. Started May 2025; status: recruiting.
02
Drugs
tegoprazan
03
Conditions
peptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT06894992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06894992.